feedback

Course Director

Jorge A. Marrero, MD, MS
Jorge A. Marrero, MD, MS

UT Southwestern Medical Center
Dallas, Texas

Faculty

Anthony El-Khoueiry
Anthony El-Khoueiry, MD

USC Norris Comprehensive Cancer Center
Los Angeles, California

Richard S. Finn
Richard S. Finn, MD

Geffen School of Medicine, University of California
Los Angeles, California, USA

Laura M. Kulik
Laura M. Kulik, MD

Northwestern University Feinberg School of Medicine
Chicago, Illinois

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2018-Dec-21
Expiration Date:2019-Dec-20
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

Optimizing patient outcomes in hepatocellular carcinoma (HCC) requires a multidisciplinary approach and understanding of the rapidly changing therapeutic landscape. Newly approved targeted and immunotherapy agents are poised to radically change the management of advanced disease, and they potentially may also have a role in earlier settings (ie, locoregional therapy). In this activity based on a recent live symposium on HCC, a multidisciplinary panel of experts offers thoughts on the current evidence supporting the use of novel systemic therapies in advanced HCC and discusses the earlier use of systemic treatment in locoregional disease. Additionally, the experts offer their insights into practical issues via patient cases through an interactive MasterClass and Tumor Board format.

Upon completion of this activity, participants should be better able to:
  • Assess the benefits and limitations of locoregional therapies in the management of HCC
  • Describe evidence on approved and emerging targeted and immuno-oncology therapeutic options in the treatment landscape for HCC
  • Employ effective strategies to monitor and manage the unique adverse effects associated with both targeted and immuno-oncology systemic therapies for HCC
  • Utilize collaborative multidisciplinary approaches to develop evidence-based treatment plans incorporating the latest therapeutic strategies for HCC, including possible clinical trial enrollment

Target Audience

This activity has been designed to meet the educational needs of hepatologists, gastroenterologists, interventional radiologists, oncologists, and other clinicians involved in the management of patients with HCC.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: December 21, 2018 - December 20, 2019
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

Jorge A. Marrero, MD, MS
Professor of Medicine
UT Southwestern Medical Center
Dallas, Texas

Jorge A. Marrero, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant for Glycotest, Inc.
Advisory Board for Eisai Inc.; Grail, Inc.; and Spring Bank Pharmaceuticals.
Other Financial or Material Support from AstraZeneca for Data Safety Monitoring Board.

Jorge A. Marrero, MD, MS, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: PD-1 inhibitors, TKIs, and VEGF-targeting antibodies, as well as novel combination approaches with LRT being assessed across HCC treatment settings.

Faculty

Anthony El-Khoueiry, MD
Associate Professor of Clinical Medicine
Medical Director of Clinical Investigations Support Office
Phase I Program Director
USC Norris Comprehensive Cancer Center
Los Angeles, California

Anthony El-Khoueiry, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer HealthCare Pharmaceuticals, Inc. and Bristol-Myers Squibb.
Grant/Research Support from AstraZeneca and Astex Pharmaceuticals.
Advisory Board for Bayer HealthCare Pharmaceuticals, Inc.; Bristol-Myers Squibb; CytomX Therapeutics; EMD Serono, Inc.; Exelixis, Inc.; Merck & Company, Inc.; and Pieris Pharmaceuticals, Inc.

Anthony El-Khoueiry, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: PD-1 inhibitors, TKIs, and VEGF-targeting antibodies, as well as novel combination approaches with LRT being assessed across HCC treatment settings.

Richard S. Finn, MD
Professor of Clinical Medicine
Division of Hematology/Oncology
Geffen School of Medicine at UCLA
Los Angeles, California

Richard S. Finn, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca; Bayer Corporation; Bristol-Myers Squibb; Eisai Inc.; Eli Lilly and Company; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.

Richard S. Finn, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: PD-1 inhibitors, TKIs, and VEGF-targeting antibodies, as well as novel combination approaches with LRT being assessed across HCC treatment settings.

Laura M. Kulik, MD
Professor of Medicine
Division of Hepatology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Laura M. Kulik, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer Corporation; Bristol-Myers Squibb; Exelixis, Inc.; and Eisai Inc.
Speakers Bureau participant with Dova Pharmaceuticals; Eisai Inc.; and Gilead.

Laura M. Kulik, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: PD-1 inhibitors, TKIs, and VEGF-targeting antibodies, as well as novel combination approaches with LRT being assessed across HCC treatment settings.

CME Reviewer

Steve S. Choi, MD

Steve S. Choi, MD, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Angela McIntosh
PVI, PeerView Institute for Medical Education

Angela McIntosh has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership


This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This educational activity is supported through medical education grants from Bayer HealthCare Pharmaceuticals Inc., Bristol-Myers Squibb, Eisai Inc., and Exelixis, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.